Literature DB >> 14521460

Latent membrane protein 1, tumor necrosis factor receptor-associated factor (TRAF) 1, TRAF-2, TRAF-3, and nuclear factor kappa B expression in posttransplantation lymphoproliferative disorders.

Preetha Ramalingam1, Wei-Sing Chu, Raymond Tubbs, Lisa Rybicki, James Pettay, Eric D Hsi.   

Abstract

CONTEXT: Most posttransplantation lymphoproliferative disorders (PTLDs) are associated with Epstein-Barr virus (EBV) infection. The EBV latent membrane protein 1 (LMP-1) is important in the transformation of B lymphocytes through its interaction with intracellular tumor necrosis factor receptor-associated factors (TRAFs) that, in turn, can activate transcription factors such as nuclear factor kappa B (NFkappaB) and Jun-N-kinase. Of the 6 members of the TRAF family, TRAF-1, TRAF-2, and TRAF-3 are most commonly associated with LMP-1. Recently, it has been suggested that LMP-1-induced TRAF activation is important in the pathogenesis of PTLDs.
OBJECTIVE: To characterize the expression patterns of these proteins in PTLDs, we studied a series of well-characterized cases for expression of LMP-1, TRAF-1, TRAF-2, TRAF-3, and NFkappaB by immunohistochemical analysis.
METHODS: A total of 27 specimens from 25 patients were analyzed for LMP-1, TRAF-1, TRAF-2, TRAF-3, and NFkappaB (active form) by immunohistochemical analysis. Expression of EBV-encoded RNA (EBER) was evaluated by in situ hybridization. Correlation between the expression of the different markers was performed using the Mantel-Haenszel chi(2) test. Cox proportional hazards analysis and Kaplan-Meier analysis with log-rank testing were used to analyze antigen expression and clinical outcome.
RESULTS: Ninety-six percent of PTLDs expressed NFkappaB, 74% to 84% expressed TRAFs, 78% expressed EBER, and 77% expressed LMP-1. TRAF-1, TRAF-2, and TRAF-3 expression did not correlate with either EBER or LMP-1 expression. TRAF-2, but not TRAF-1 or TRAF-3, expression correlated with NFkappaB expression (P =.02).
CONCLUSIONS: These results suggest that TRAF molecules and active NFkappaB are expressed in PTLDs regardless of EBV positivity. Given the association of TRAF-2 and active NFkappaB expression, TRAF-2 may play an important role in regulating this transcription factor in PTLD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14521460     DOI: 10.5858/2003-127-1335-LMPTNF

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expression.

Authors:  Alexis Proust; Patricia Rincé; Rita Creidy; Thierry Lazure; Irène Joab; Loïc Garçon; Monique Fabre; Catherine Guettier; Martine Raphael
Journal:  Am J Pathol       Date:  2011-08-24       Impact factor: 4.307

2.  The Epstein-Barr virus LMP1 interactome: biological implications and therapeutic targets.

Authors:  Mujeeb R Cheerathodi; David G Meckes
Journal:  Future Virol       Date:  2018-12-03       Impact factor: 1.831

3.  Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.

Authors:  Ping Zou; Junichi Kawada; Lesley Pesnicak; Jeffrey I Cohen
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

Review 4.  HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma.

Authors:  J I Cohen
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.